Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Leerink Swann decreased their Q3 2018 EPS estimates for shares of Aurinia Pharmaceuticals in a report issued on Monday, August 13th. Leerink Swann analyst J. Schwartz now expects that the company will post earnings of ($0.25) per share for the quarter, down from their prior estimate of ($0.24). Leerink Swann also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($1.00) EPS and FY2019 earnings at ($1.16) EPS.

Shares of AUP stock opened at C$6.98 on Thursday. Aurinia Pharmaceuticals has a 1-year low of C$5.68 and a 1-year high of C$9.50.

Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last issued its quarterly earnings results on Thursday, August 9th. The company reported C($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.21) by C($0.04). Aurinia Pharmaceuticals had a negative net margin of 45,241.38% and a negative return on equity of 30.41%. The business had revenue of C$0.04 million for the quarter, compared to analysts’ expectations of C$0.07 million.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: Marijuana Stocks Investing Considerations

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with's FREE daily email newsletter.